Latest Cancer Therapeutics News

Page 1 of 2
INOVIQ Limited has reported compelling preclinical results for its CAR-NK-exosome therapy targeting triple-negative breast cancer, showing significant tumor reduction and perfect survival in treated mice.
Ada Torres
Ada Torres
22 Dec 2025
Invion Limited has secured a pivotal FDA Orphan Drug Designation for its lead cancer drug INV043, bolstered its balance sheet with nearly $1.8 million in new funding, and progressed clinical trials targeting skin and anogenital cancers.
Ada Torres
Ada Torres
31 Oct 2025
Invion Limited has partnered with Protect Animal Health to explore Photosoft™, a novel photodynamic therapy, as a treatment for cancer in companion animals, targeting a booming pet cancer market.
Ada Torres
Ada Torres
21 Oct 2025
INOVIQ Limited has launched an A$11.5 million capital raise to fast-track clinical validation and commercialization of its ovarian cancer screening test and advance its CAR-exosome therapeutic program targeting solid tumors.
Ada Torres
Ada Torres
13 Oct 2025
Invion Limited has secured $0.8 million through convertible notes to repay its Lind Global Fund II LP facility and support working capital, positioning itself for potential global licensing deals of its Photosoft technology.
Victor Sage
Victor Sage
10 Oct 2025
Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial expansion and strategic investments in R&D and manufacturing. The company confirms full-year guidance while advancing key clinical trials and product launches.
Ada Torres
Ada Torres
21 Aug 2025
Telix Pharmaceuticals reported a robust 63% increase in revenue to $390.4 million for the first half of 2025, driven by strong Illuccix sales and the acquisition of RLS Radiopharmacies. Despite this growth, the company recorded a net loss of $2.3 million, reflecting increased investments and finance costs.
Ada Torres
Ada Torres
21 Aug 2025
INOVIQ Limited reports breakthrough results for its ovarian cancer screening test achieving perfect early-stage detection, alongside promising advances in its CAR-exosome cancer therapy program.
Ada Torres
Ada Torres
31 July 2025
Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase to $204 million in Q2 2025, launched its new prostate cancer imaging agent Gozellix in the U.S., and advanced key clinical trials despite an ongoing SEC inquiry.
Ada Torres
Ada Torres
22 July 2025
INOVIQ Limited has responded to ASX queries defending its announcement that its new CAR-NK-EV treatment killed 88% of breast and lung cancer cells in vitro, confirming compliance with disclosure rules and providing detailed study data.
Ada Torres
Ada Torres
23 June 2025
INOVIQ Limited has announced a breakthrough in its cancer treatment program, with its CAR-exosome therapy killing 88% of triple negative breast and lung cancer cells in laboratory studies. This innovation could pave the way for faster, safer, and more accessible cancer therapies.
Ada Torres
Ada Torres
18 June 2025
INOVIQ's December quarterly update reveals significant progress in its cancer diagnostic and therapeutic programs, including a highly accurate ovarian cancer screening test and promising breast cancer therapeutics, supported by growing EXO-NET customer adoption and a solid cash position.
Ada Torres
Ada Torres
31 Jan 2025